Cytokinetics (CYTK) Liabilities and Shareholders Equity (2016 - 2025)
Historic Liabilities and Shareholders Equity for Cytokinetics (CYTK) over the last 16 years, with Q3 2024 value amounting to $1.4 billion.
- Cytokinetics' Liabilities and Shareholders Equity rose 9390.13% to $1.4 billion in Q3 2024 from the same period last year, while for Dec 2024 it was $3.8 billion, marking a year-over-year increase of 1648.67%. This contributed to the annual value of $824.3 million for FY2023, which is 1876.86% down from last year.
- Cytokinetics' Liabilities and Shareholders Equity amounted to $1.4 billion in Q3 2024, which was up 9390.13% from $1.5 billion recorded in Q2 2024.
- Over the past 5 years, Cytokinetics' Liabilities and Shareholders Equity peaked at $1.5 billion during Q2 2024, and registered a low of $232.5 million during Q2 2020.
- Its 5-year average for Liabilities and Shareholders Equity is $791.0 million, with a median of $808.1 million in 2024.
- In the last 5 years, Cytokinetics' Liabilities and Shareholders Equity soared by 15300.41% in 2020 and then tumbled by 3116.72% in 2023.
- Cytokinetics' Liabilities and Shareholders Equity (Quarter) stood at $533.8 million in 2020, then surged by 57.61% to $841.3 million in 2021, then grew by 20.62% to $1.0 billion in 2022, then decreased by 18.77% to $824.3 million in 2023, then surged by 74.21% to $1.4 billion in 2024.
- Its Liabilities and Shareholders Equity was $1.4 billion in Q3 2024, compared to $1.5 billion in Q2 2024 and $808.1 million in Q1 2024.